Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: A call for participation

Thyroid

Volumn 23, Issue 4, 2013, Pages 517-519

  Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PAZOPANIB; RADIOACTIVE IODINE; SUNITINIB; VANDETANIB; VASCULOTROPIN; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ALLELIC IMBALANCE; ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CELL POPULATION; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENE MUTATION; HUMAN; LETTER; LIFE EXPECTANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; WILD TYPE; THYROID TUMOR;

HUMANS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84875757400     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0614     Document Type: Letter

References (23)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
2. Crouzeix G, Michels JJ, Sevin E, Aide N, Vaur D, Bardet S 2012 Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 97:3046-3050.
3. Sherman SI 2010 Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22:464-468.
4. Marotta V, Ramundo V, Camera L, Prete MD, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A 2012 Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-ET. Clin Endocrinol (Oxf) 2012 Sep 25 [Epub ahead of print]; DOI: 10.1111/cen.12057.
5. Ferrara N 2002 VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803.
6. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737-1742.
7. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL 2002 Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953-961.
8. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W 2012 SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med 209:1289-1307.
9. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
10. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F 2003 Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through theMEK/ERK pathway. J Biol Chem 278:42409-42418.
11. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793.
12. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S 2011 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309.
13. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P, Thomas G 2004 Heterogeneity in the distribution of RET/PTC rearrangements within individual post- Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab 89:4272-4279.
14. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 96:E916-919.
15. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 58:31-38.
16. Vitale M 2012 Rethinking the role of oncogenes in papillary thyroid cancer initiation. Front Endocrinol (Lausanne) 3:83.
17. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524.
18. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M 2012 A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97:2333-2340.
19. Vasko V, Hu S,Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265-5269.
20. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68:618-634.
21. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A 2012 BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97:E1745-1749.
22. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK 2008 Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 215:145-154.
23. Xing M 2012 BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab 97:2295- 2298.